标题：Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results
期刊名称：Annals of Agricultural and Environmental Medicine
印刷版ISSN：1232-1966
电子版ISSN：1898-2263
出版年度：2018
卷号：25
期号：1
页码：56-59
DOI：10.5604/12321966.1233571
出版社：Institute of Agricultural Medicine in Lublin
摘要：Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases ofthe disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeuticoptions.Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL)treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland,during 2011–2013.Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, aftera few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab incombination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study werediagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy.Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cellsreturned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completionof immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymphnodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patientpartial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia andan infection with Candida glabrata were observed.Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
